GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (FRA:BM8) » Definitions » PEG Ratio

Biomarin Pharmaceutical (FRA:BM8) PEG Ratio : 0.33 (As of Mar. 24, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Biomarin Pharmaceutical's PE Ratio without NRI is 25.45. Biomarin Pharmaceutical's 5-Year EBITDA growth rate is 78.10%. Therefore, Biomarin Pharmaceutical's PEG Ratio for today is 0.33.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Biomarin Pharmaceutical's PEG Ratio or its related term are showing as below:

FRA:BM8' s PEG Ratio Range Over the Past 10 Years
Min: 0.29   Med: 0.33   Max: 0.43
Current: 0.33


During the past 13 years, Biomarin Pharmaceutical's highest PEG Ratio was 0.43. The lowest was 0.29. And the median was 0.33.


FRA:BM8's PEG Ratio is ranked better than
93.14% of 102 companies
in the Biotechnology industry
Industry Median: 1.455 vs FRA:BM8: 0.33

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Biomarin Pharmaceutical PEG Ratio Historical Data

The historical data trend for Biomarin Pharmaceutical's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical PEG Ratio Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.31

Biomarin Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.33 0.31

Competitive Comparison of Biomarin Pharmaceutical's PEG Ratio

For the Biotechnology subindustry, Biomarin Pharmaceutical's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's PEG Ratio falls into.



Biomarin Pharmaceutical PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Biomarin Pharmaceutical's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=25.451040863531/78.10
=0.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Biomarin Pharmaceutical  (FRA:BM8) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Biomarin Pharmaceutical PEG Ratio Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines